Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PEDS024, Phase I/II Feasibility Study of Busulfan Fludarabine and Thiotepa Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) for Children With Non-Malignant Disorders

NCT03513328 is registered in ClinicalTrials.gov with University of Florida as lead sponsor.

NCT NCT03513328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03513328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PEDS024, Phase I/II Feasibility Study of Busulfan Fludarabine and Thiotepa Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) for Children With Non-Malignant Disorders
Lead sponsor
University of Florida
Phase
Phase 1/2
Overall status
Completed
Start date
June 15, 2018
Completion date
February 19, 2023
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acquired anemia hemolytic, acquired neutropenia in newborn, acquired thrombocytopenia, adrenoleukodystrophy, bone marrow failure syndrome, chronic granulomatous disease, common variable immunodeficiency, diamond blackfan anemia, hemophagocytic lymphohistiocytoses, hurler syndrome, mannosidosis, severe combined immunodeficiency, sickle cell disease, thalassemia, wiskott-aldrich syndrome, x-linked lymphoproliferative disease